Table 2.
Patients’ characteristics and levels of CMTM1_v17 expression pre- and post-NAC (n = 31)
| Variable | Pre-NAC | Post-NAC | ||||
|---|---|---|---|---|---|---|
| CMTM1_v17 expression no. (%) | P value | CMTM1_v17 expression no. (%) | P value | |||
| High | Low | High | Low | |||
| Age | 0.200 | 0.552 | ||||
| ≤ 55 | 7(43.8) | 9(56.3) | 7(43.8) | 9(56.2) | ||
| > 55 | 10(66.7) | 5(33.3) | 5(33.3) | 10(66.7) | ||
| Gender | 0.763 | 0.791 | ||||
| Male | 10(40.0) | 15(60.0) | 14(56.0) | 11(44.0) | ||
| Female | 2(33.3) | 4(66.7) | 3(50.0) | 3(50.0) | ||
| Smoking history | 0.935 | 0.75 | ||||
| Non-smoker | 3(37.5) | 5(62.5) | 4(50.0) | 4(50.0) | ||
| Smoker | 9(39.1) | 14(60.9) | 13(56.5) | 10(43.5) | ||
| Histology | 0.332 | 0.981 | ||||
| Adenocarcinoma | 3(27.3) | 8(72.7) | 6(54.5) | 5(45.5) | ||
| Non-adenocarcinoma | 9(45.0) | 11(55.0) | 11(55.0) | 9(45.0) | ||
| Histologic grading | 0.379 | 0.576 | ||||
| Poorly | 5(31.3) | 11(68.7) | 8(50.0) | 8(50.0) | ||
| Moderate and well | 7(46.7) | 8(53.3) | 9(60.0) | 6(40.0) | ||
| Venous invasion | 0.355 | 0.75 | ||||
| Negative | 10(43.5) | 13(56.5) | 13(56.5) | 10(43.5) | ||
| Positive | 2(25.0) | 6(75.0) | 4(50.0) | 4(50.0) | ||
| Pathological stage | 0.756 | 0.092 | ||||
| I/II | 7(41.2) | 10(58.8) | 7(41.2) | 10(58.8) | ||
| III | 5(35.7) | 9(64.3) | 10(71.4) | 4(28.6) | ||
P value was calculated using Pearson’s χ2 test
NAC neoadjuvant chemotherapy